Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Brian Elsbernd Sells 62,975 Shares of Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Catalyst Pharmaceuticals Trading Down 1.0 %

NASDAQ CPRX opened at $21.89 on Thursday. The business’s 50-day moving average price is $22.27 and its 200 day moving average price is $21.49. Catalyst Pharmaceuticals, Inc. has a twelve month low of $14.47 and a twelve month high of $24.64. The company has a market capitalization of $2.66 billion, a PE ratio of 18.55, a price-to-earnings-growth ratio of 3.31 and a beta of 0.80.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CPRX. Castlekeep Investment Advisors LLC purchased a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $37,494,000. Bank of America Corp DE lifted its stake in shares of Catalyst Pharmaceuticals by 139.5% in the 4th quarter. Bank of America Corp DE now owns 1,568,791 shares of the biopharmaceutical company’s stock valued at $32,741,000 after purchasing an additional 913,843 shares in the last quarter. abrdn plc purchased a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth about $10,115,000. Arrowstreet Capital Limited Partnership lifted its position in Catalyst Pharmaceuticals by 131.4% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 698,152 shares of the biopharmaceutical company’s stock valued at $14,570,000 after buying an additional 396,506 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 4.9% during the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company’s stock valued at $175,957,000 after acquiring an additional 390,116 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Analyst Ratings Changes

CPRX has been the subject of several research reports. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Robert W. Baird raised their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Finally, Truist Financial boosted their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $32.50.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.